isosorbide-5-mononitrate has been researched along with Cerebral Small Vessel Diseases in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (25.00) | 24.3611 |
2020's | 3 (75.00) | 2.80 |
Authors | Studies |
---|---|
Appleton, JP; Bath, PM; Blair, GW; Chappell, F; Doubal, FN; Flaherty, K; Hamilton, I; Janssen, E; Shi, Y; Stringer, MS; Thrippleton, MJ; Wardlaw, JM | 1 |
Bath, PM; Doubal, F; Mhlanga, I; Montgomery, AA; Oatey, K; Wardlaw, JM; Woodhouse, LJ | 1 |
Bamford, J; Bath, PM; Cvoro, V; Doubal, FN; England, T; Hassan, A; Heye, AK; Mhlanga, II; Montgomery, A; O'Brien, JT; Oatey, K; Roffe, C; Sprigg, N; Wardlaw, JM; Werring, DJ; Woodhouse, LJ | 1 |
Appleton, JP; Bath, PM; Blair, GW; Boyd, J; Dooley, R; Doubal, F; Flaherty, K; Hamilton, I; Law, ZK; Richardson, C; Shi, Y; Shuler, K; Sprigg, N; Stringer, M; Thrippleton, MJ; Wardlaw, JM | 1 |
4 trial(s) available for isosorbide-5-mononitrate and Cerebral Small Vessel Diseases
Article | Year |
---|---|
Effects of Cilostazol and Isosorbide Mononitrate on Cerebral Hemodynamics in the LACI-1 Randomized Controlled Trial.
Topics: Aged; Cerebral Small Vessel Diseases; Cilostazol; Female; Hemodynamics; Humans; Isosorbide Dinitrate; Lipoproteins; Magnetic Resonance Imaging; Male; Middle Aged; Treatment Outcome; Vasodilator Agents | 2022 |
Cilostazol and isosorbide mononitrate for the prevention of progression of cerebral small vessel disease: baseline data and statistical analysis plan for the Lacunar Intervention Trial-2 (LACI-2) (ISRCTN14911850).
Topics: Brain Ischemia; Cerebral Small Vessel Diseases; Cilostazol; Female; Humans; Middle Aged; Prospective Studies; Stroke; Stroke, Lacunar | 2023 |
Isosorbide Mononitrate and Cilostazol Treatment in Patients With Symptomatic Cerebral Small Vessel Disease: The Lacunar Intervention Trial-2 (LACI-2) Randomized Clinical Trial.
Topics: Aged; Cerebral Small Vessel Diseases; Cilostazol; Female; Humans; Male; Middle Aged; Quality of Life; Stroke; Stroke, Lacunar; Treatment Outcome | 2023 |
Preventing cognitive decline and dementia from cerebral small vessel disease: The LACI-1 Trial. Protocol and statistical analysis plan of a phase IIa dose escalation trial testing tolerability, safety and effect on intermediary endpoints of isosorbide mon
Topics: Age Factors; Cerebral Small Vessel Diseases; Cilostazol; Cognition Disorders; Dementia; Double-Blind Method; Female; Follow-Up Studies; Humans; Isosorbide Dinitrate; Magnetic Resonance Imaging; Male; Neuropsychological Tests; Severity of Illness Index; Treatment Outcome; United Kingdom; Vasodilator Agents | 2018 |